亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Non Insulin Based Type 2 Diabetes Therapy

技術優勢: The inventors have developed novel molecules that have been demonstrated to be safe and effective in an animal model of diabetes (rodent) Can be taken orally unlike insulin, eliminating the need for painful injections As an a therapy which restores the body's ability to regulate blood glucose on its own, it will lead to better real time glucose management, alleviating the deleterious health effects of hyperglycemia A metabolic precursor to this molecule has been used for 5 decades to treat unrelated conditions and has proven itself to be safe and well tolerated by patients Most current therapies have adverse side effects, including hypoglycemia (low blood sugar) and weight gain, this may eliminate those

技術應用: A new, non-insulin based therapy for type 2 diabetes to aid the body's native insulin response to blood glucose levels, may be used independently or in conjunction with other therapies Use of a radiolabeled variant of the inhibitor to target beta cells in the pancreas and quantify progression of disease based on degree of labeling

詳細技術說明: One of the factors contributing to type 2 diabetes is impaired beta cell function and loss of response to hyperglycemic stimulus. The invention is a novel inhibitor of an ATP dependent transporter molecule expressed in beta cells, which is responsibl...

*Inquiry: Peter GolikovColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*Publications: Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas, J Mol Histol. 2008 Oct;39(5):543-51

欲了解更多信息，請點擊這裡